The goal of the Protocol Review and Monitoring System (PRMS) is to provide scientific oversight of cancer clinical trials conducted at City of Hope Comprehensive Cancer Center independent of the protection of human subjects afforded through the COM Institutional Review Board (IRB). This function is organized around the Cancer Center's Cancer Protocol Review and Monitoring Committee (CPRMC). City of Hope supports an internal Cancer Protocol Review and Monitoring Committee (CPRMC) to: 1) maintain the high quality of institutional clinical research;2) prioritize clinical research conducted by Cancer Center members; 3) provide a pathway for innovative clinical protocol research in the diagnosis, therapy, prevention and control of cancer to gain full access to shared resources and services supported by the Cancer Center Support Grant (CCSG). Scientific review requiring full committee vote is required for all new trials, amendments to on-going trials, and continuing trials?the latter on a yearly basis. The scientific review for new trials includes an evaluation of study design, scientific rationale, potential for accrual and biostatistical input for all new studies. Review of annual continuations includes an examination of actual accrual. Investigator-initiated Cancer Center-supported clinical protocols cannot have access to any of the Center's core facilities without full approval of the study by the CPRMC. Data and safety monitoring is conducted in compliance with the NCI-approved Data and Safety Monitoring Plan for Cancer Clinical Trials. This level of review provides an independent means of confirming the efficacy of the investigational treatment programs ongoing in the Cancer Center. The total annual budget of the CPRMC is $125,483 of which the institution pays 52% and CCSG funding is requested for $ 60,819, or 48% of the total. Total staffing for the core is 2.99 FTEs.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
City of Hope/Beckman Research Institute
United States
Zip Code
Gu, Ying; Zhang, Jiawei; Ma, Xiaoxiao et al. (2017) Stabilization of the c-Myc Protein by CAMKII? Promotes T Cell Lymphoma. Cancer Cell 32:115-128.e7
Cao, Pengpeng; Mooney, Rachael; Tirughana, Revathiswari et al. (2017) Intraperitoneal Administration of Neural Stem Cell-Nanoparticle Conjugates Targets Chemotherapy to Ovarian Tumors. Bioconjug Chem 28:1767-1776
Mohanty, Suchismita; Mohanty, Atish; Sandoval, Natalie et al. (2017) Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines. Leuk Lymphoma 58:676-688
Wittenberg, Elaine; Ferrell, Betty; Koczywas, Marianna et al. (2017) Pilot Study of a Communication Coaching Telephone Intervention for Lung Cancer Caregivers. Cancer Nurs :
Yuan, Yuan; Vora, Nilesh; Sun, Can-Lan et al. (2017) Association of Pre-Chemotherapy Peripheral Blood Pro-Inflammatory and Coagulation Factors with Physical Function in Women with Breast Cancer. Oncologist 22:1189-1196
Deng, Ruishu; Hurtz, Christian; Song, Qingxiao et al. (2017) Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. Nat Commun 8:978
He, Zhiheng; Ma, Jian; Wang, Ruiqing et al. (2017) A two-amino-acid substitution in the transcription factor ROR?t disrupts its function in TH17 differentiation but not in thymocyte development. Nat Immunol 18:1128-1138
Kortylewski, Marcin; Moreira, Dayson (2017) Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. Cancer Immunol Immunother 66:979-988
Somlo, George; Frankel, Paul H; Arun, Banu K et al. (2017) Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res 23:4066-4076
Slavin, Thomas P; Neuhausen, Susan L; Nehoray, Bita et al. (2017) The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Fam Cancer :

Showing the most recent 10 out of 1277 publications